ELAVL1 and familial pancreatic carcinoma: By potentially exploiting these interactions via targeting of GPRC5A mRNA we can increase the death rate of pancreatic cancer cells following treatment by gemcitabine or Trichostatin A. The increased abundance of GPRC5A in human cancer cell lines, TCGA cancer samples, and pancreatic cancer primary tumors and metastases, and the additional evidence we presented above, namely GPRC5A's interactions with HuR and gemcitabine as well as other potential chemo-drugs, suggest a possible pro-oncogenic role for this gene.